Production / Operations
HEALWELL AI and WELL Health Launch WELLTRUST to Empower Patients and Accelerate AI Powered Ethical Patient Identification for Clinical Research

AIDX · Price
Executive Summary
- HEALWELL AI Inc. and WELL Health Technologies Corp. announced the launch of WELLTRUST™, a consent‑driven patient‑identification platform for clinical research across WELL‑operated clinics in Canada.
- The platform combines WELL’s extensive outpatient clinic network with HEALWELL’s DARWEN™ AI to securely match high‑fit patients with chronic, rare, and complex conditions to clinical trial opportunities while preserving privacy.
- WELLTRUST provides a scalable, privacy‑compliant infrastructure that enables pharmaceutical sponsors and research organizations to access consented patient data for trial recruitment, real‑world evidence generation, and future decision‑support tools.
Key Details
- Platform Name: WELLTRUST™ – “consent‑first” data governance and patient‑identification solution.
- Collaborators: HEALWELL AI Inc. (TSX: AIDX) and WELL Health Technologies Corp. (TSX: WELL).
- Geographic Scope: Initial rollout in Canada within WELL‑operated outpatient clinics (Toronto, Ontario; Vancouver, British Columbia, and other locations).
- Core Functionality:
- Secure patient consent framework allowing individuals to opt‑in or opt‑out of future outreach for clinical trials and research studies.
- AI‑enabled identification of “high‑fit” patients using HEALWELL’s DARWEN™ platform, targeting chronic, rare, and complex conditions.
- Unified privacy, consent, and data‑governance layer meeting Canadian regulatory standards.
- First Commercial Application: Leveraging the combined clinical footprint and AI to accelerate recruitment for clinical trials, improving enrollment rates and trial success probability.
- Future Use Cases (planned): Real‑world evidence generation, enhanced clinical decision support tools, and additional research‑related data services.
- Quotes:
- Dr. Alexander Dobranowski, President, HEALWELL AI – highlighted the platform’s role in responsible AI and patient autonomy.
- Dr. Michael Frankel, Chief Medical Officer, WELL Health – emphasized the impact on accelerating therapeutics and diagnostics through a transparent, consent‑driven data infrastructure.
- Leadership Sign‑off: James Lee (CEO, HEALWELL AI) and Hamed Shahbazi (Chairman & CEO, WELL Health).
Notable Quotes
“WELLTRUST embodies our commitment to responsible and impactful AI in healthcare…accelerating research while respecting high standards of privacy and patient autonomy.” – Dr. Alexander Dobranowski, President, HEALWELL AI
“This launch marks a major step forward in our mission to empower patients and improve healthcare outcomes through the use of technology.” – Dr. Michael Frankel, Chief Medical Officer, WELL Health
More from HEALWELL AI INC. J CL A SV
Jun 17, 2026 · 12:10